KR910005409B1 - Process for preparing specific antibody containing substance from eggs - Google Patents

Abstract

No content.

Description

Method for preparing specific antibody-containing material from eggs

1 is a graph showing the weekly rate of change of antibody titers in the yolk of hens immunized against 987P ⁺ antigen of E. coli (ETEC) in swine.

FIG. 2 is a graph depicting the rate of change in body temperature of newborn piglets after 987P ⁺ ETEC challenge in the control group administered orally with the yolk powder recovered from the hen's eggs immunized against the same antigen.

3 is a graph showing the weight gain rate of newborn piglets after 987P ⁺ ETEC attack.

The present invention relates to a specific antibody-containing material prepared from eggs of a hen immunized against a selected antigen, containing an antibody specific for the antigen, a method for producing the same, and a use thereof. The present invention also relates to a material prepared from the eggs of a hen immunized against a selected antigen and containing a transelement component specific for the antigen, a method for producing the same and a use thereof.

U.S. Patent No. 4,402,938 (Collins et al.) Inoculates an antigen into the breast of an ungulate animal before delivery, collects the milk secreted after colostrum and colostrum after delivery, and removes fat and solids from the whey ( After obtaining i), the whey is ultrafiltered with a filter having a pore size of about 0.2 micron, and a method for obtaining a product containing an unknown nutrient having a molecular weight of 1200 or less as a filtrate is disclosed. According to this method, the antigenic substance is selected from pollen, bacteria, viruses, fungi, allergens, blood, sperm and toxins extracted from diseased animals. Products containing these nutrients are useful as nutritional supplements for animals.

According to the above method, however, the antigen must be administered to the ungulate animal of the last month of pregnancy, and the subject to be collected contains colostrum as an essential ingredient, but the secretion period is extremely limited to several days after delivery. It is therefore very difficult to continue to use the method in countries with limited farmland, such as Japan or the United Kingdom, since large scale farms must be secured to produce large quantities of the above mentioned nutrients.

Furthermore, the method disclosed in the above-mentioned US patent involves a very complex process which requires refrigeration for 60 days or longer to separately treat colostrum and subsequent collected milk and to precipitate and remove solids.

In addition, the above-mentioned U.S. Patent discloses that the product obtained by ultrafiltration using a filter having a pore size of about 0.2 micron is a nutrient and B lysine, conglutinin, inteferon, lactoferrin, lactoperoxidase, B lymphocytes, T lymphocytes, and lysozyme. , Macrophages, polypeptides, properdin and thiocyanate and the like, but have been described for the removal of proteins, globulins and other large molecules with molecular weights greater than 1200. However, these molecules, which are removed from the product and not used in the method, contain useful active materials such as globulins and contain specific antibodies to the antigens used for immunization, which specific antibodies may be present when the animal is exposed to the same antigen. Has the ability to protect animals

When a specific antibody generated in an animal's body by immunization against an antigen is administered to another animal, the animal to which the specific antibody has been administered is passively immunized against the antigen, and therefore, is attacked or infected by the same antigen as that used for immunization. It is well known in the art that it can be effectively protected. However, unless the antibody-immunized and immunized animals are the same species, repeated administration of the antibody to the animal due to the specific reaction with the heterologous antibodies produced in the animal's body at the first dose causes a shock. For this reason, the protection achieved by passive immunization with heterologous antibodies generally applies only to treatment for emergencies, for example, for tetanus or snake bites.

Specific antibodies or specific antibody-containing fractions isolated from bovine milk or chicken eggs immunized against the antigen feed animals with heterologous antibody-containing materials such as milk or eggs for prolonged periods (30-90 days). Japanese Patent Publication No. 60-248628 discloses that an animal can obtain resistance to heterologous antibodies in chickens or cattle, thereby allowing the animal to have a heterogeneous passive immunity against attack of the same antigens used for immunization. Described. In Example 2 of the disclosure, the antibody-containing fraction of the egg was injected twice into rabbits that did not acquire resistance to the antibody. As a result, all animals died of sensitivity shock.

Therefore, the passive immunization method disclosed in the above disclosure requires a long time of 30 days or more before the animal is treated by passive immunization method using an egg or small antibody. This means that it is very difficult to apply to the treatment of actual infectious diseases. Moreover, since the time required to obtain resistance to the antibody is largely dependent on the species, age and health of the animal, the method always carries the risk of developing serum diseases or even severe shock by co-administering the antibody.

In the Japanese Laid-Open Patent Application, there is no experimental data on what therapeutic effect is obtained by administering a specific antibody to an animal that has obtained resistance to the antibody. Only therapeutic experiments are shown in Example 3 of the Published Application, in which an oocyte antibody against anthracite typhoid (Serotype C) was orally administered to sterile mice that did not acquire resistance to the oocyte antibody. After 20 days of repeated administration, these animals were attacked by bacteria of the same species. The results were evaluated by the number of spots found in the molars. However, there were no statistically significant differences in the results for antibody and control groups. Furthermore, experiments were conducted on germ-free mice that could not survive naturally by oral administration of mucosa streptococcus, a bacterium that causes caries in humans rather than mice. Therefore, this experiment does not provide reliable data on the therapeutic effect obtained by administering an antibody or an antibody-containing fraction disclosed in the application.

It is well known that many infectious diseases of livestock and poultry, such as pigs and chickens, can be prevented by oral administration of antibodies to the bacteria that cause them. For this purpose, methods for preparing and administering materials containing antibodies or antibody-like factors have been proposed in this field. For example, US Pat. Nos. 4,402,938 and 3,984,539 and 4,284,623 described above can be found. Most known methods, however, use bovine serum, colostrum or milk to prepare antibodies or antibody-like factors. Therefore, these methods are readily simple and cannot be performed in Japan or other countries with limited farmland, and the products thus produced are too expensive.

In addition to preventing the infectious diseases in animals, materials containing specific antibodies or antibody-like factors are useful in animal feed and poultry feed additives, cosmetics, pharmaceuticals and in the field of serum diagnostics. It is therefore desirable to provide antibodies or antibody-like factors specific for materials or selected antigens containing antigens or antigen-like factors that can be prepared in large quantities at low cost.

It is an object of the present invention to provide a method for preparing a material containing a specific antibody or a transfactor component as an active ingredient, and to provide a method for producing such a material in a large amount at low cost in any season of the year.

Another object of the present invention is to provide an inexpensive material containing a specific antibody or a transfactor component as an active ingredient prepared from the eggs of a hen immunized against a selected antigen.

It is a further object of the present invention to provide the use of such materials containing specific antibody or transfactor components as active ingredients in infectious diseases or other treatments and as additives to feed, cosmetics and pharmaceutical products of livestock and poultry.

Other objects, advantages and features of the present invention will become apparent from the following description. In one aspect, the present invention provides an oral specific antibody-containing material obtained from the egg whole or egg yolk or egg white of a hen immunized with a selected antigen. This material contains antibodies specific for antigens used to immunize hens and is active against antigens. Therefore, according to the present invention, the preferred antibody-containing material is made from eggs, and thus it is possible to produce a large amount inexpensively in any season of the year. The specific antibody-containing material may be a specific antibody, itself (i.e., immunoglobulin fraction), which has been separated from the egg whole, yolk or egg white by a conventional method. In a preferred embodiment, however, whole eggs, yolks or whites containing specific antibodies are stirred or homogenized into emulsions and spray dried to form powders and recovered as preferred antibody-containing materials according to the invention. This powder is orally administered to animals with intestinal infectious diseases.

In another aspect, the present invention provides oral and parenteral materials containing a specific transfactor component and obtained from fractions having a molecular weight of 10,000 or less of egg whole or yolk or white of hens immunized against a selected antigen. . The transfactor components contained in this material are specific for the antigen used to immunize and have activity against chronic type hypersensitivity passive metastasis. Such materials do not contain antibodies or immunoglobulins and can therefore be used for parenteral use. It is particularly useful for the treatment of various infectious diseases other than intestinal infectious diseases, and for use in animal and poultry feed additives, cosmetics and pharmaceuticals. The material other than fractions of molecular weight of 10,000 or less isolated for preparation contain the antibodies specific for the selected antigen and are useful for preparing the specific antibody-containing materials described in the paragraphs above.

In order to prepare a specific antibody-containing material or a specific transfer factor component-containing material according to the present invention, a hen must be immunized against a selective antigen. The antigen may be any substance to which the animal's immune system responds and is selected depending on the intended use of the material to be produced. Antigens used in the methods of the invention are selected from pollen, bacteria, viruses, fungi, allergens, blood, sperm and toxins extracted from diseased animals. In addition, two or more antigens may be used in combination or polyvalent antigens may be used.

In preparing specific antibody-containing materials, the antigen is preferably selected from pathogenic bacteria or factors causing intestinal infectious diseases in animals. The use of such materials in the treatment or prevention of intestinal infections is particularly useful because the antibody-containing materials according to the invention are administered to animals only orally to avoid the risk of causing serum disease or sensitive shock. Particularly suitable pathogenic bacteria or factors for use in preparing the antibody-containing material of the present invention are E. coli bacteria or factors that cause Escherichia coli (especially diarrhea, such as swine scouts in young animals such as piglets or calves). Specific examples of such bacteria or factors include swine ETEC 987P, K88 and K99 antigens. E. coliosis is a serious problem in livestock farms because newborn piglets or calves often do not get enough immunoglobulin from colostrum, so many young piglets and calves have E. coli and scouts with severe diarrhea and dehydration. It also results in frequent deaths.

In preparing materials containing transition factor components from fractions with molecular weight of 10,000 or less of egg yolk or egg white or egg whole, these materials do not contain any antibodies and therefore parenterally without risk of causing serum diseases and sensitive shock. Since it can be used, the antigen used for this purpose is selected from a wide variety of substances listed above which serve as antigens in animals.

When a material of the present invention containing a specific antibody or a transfactor component is used as an animal feed additive, the antigen used for immunization is derived from inactive antigens, supervisory antigens and subunit antigens. It is preferred to be selected.

Immunization of hens against selected antigens can be accomplished by inoculating the antigens by appropriate routes such as subcutaneous, intraperitoneal, intramuscular, intravenous or oral administration. In order to increase immunity, it is preferable to administer an appropriate adjuvant together with the antigen. Adjuvant useful for this purpose is a water-in-oil emulsion adjuvant, such as a complete Freund's adjuvant. The use of an appropriate adjuvant is quite effective in keeping the antibody titer in the eggs of the immunized hens high for a long time, thereby effectively producing the desired antibody-containing material. The inoculation amount of the antigen is determined by the type of the antigen and the adjuvant, and the route of administration in the method of producing an immune state in which the excess antigen itself is not toxic in the hen. In general, within a few weeks of inoculation (first immunization) the hen becomes sensitive to the antigen. That is, they are immune to antigen. Antibodies specific to the antigen are produced in the hen's body, and the eggs laid by the hen contain specific antibodies. The presence and titer levels of specific antibodies to antigens in hens and eggs can be confirmed by various methods known to those skilled in the immunological field of experiments.

One or more promoters are administered in an appropriate amount to maintain a high antibody titer in the hen after initially immunizing the hen against the antigen. In addition, at the time of administration of each promoter, an appropriate adjuvant can be used together with the antigen. The time interval between the first immunization and the first promoter administration and the time interval between each promoter administration depends on the type of antigen and is preferably at least 2 weeks.

After confirming that the appropriate amount of the specific antibody of interest is contained in the eggs laid by the immunized hen, eggs are collected and stored until needed. Conveniently, a number of eggs from one or more hens immunized against the same antibody are collected and processed together to produce the desired material containing antibodies or transfactor components specific for the antigen.

That is, the whole egg or the yolk or white of each egg are separated from the collected eggs or eggs. Since most antibodies are contained in the egg yolks, they are usually isolated for use in preparing the desired material. However, specific antibodies to certain antigens are believed to be present mainly in the egg whites, so if such antigens are used to immunize hens, the whites can be used in the method of the present invention. In some cases, egg yolks and egg whites are used together.

The isolated yolk or white or whole whole containing the antibody to the inoculated antigen is then homogenized or vigorously stirred to make an emulsion antibody. If desired, water can be added to this homogenate. In a preferred embodiment, the emulsion is immediately dried to a powder by conventional methods such as spray drying or lyophilization which do not cause severe destruction of antibody activity. The powder thus formed contains a specific antibody and is used as an antibody-containing material for oral administration according to the present invention. According to this example, the desired specific antibody-containing substrate is prepared without the complicated process of separating the immunoglobulin fraction from the emulsion. This separation process has generally been used in prior art relating to the production of antibody-containing materials.

If the antigen used to immunize a hen is a bacterium that causes an intestinal infectious disease, such as calf or swine colitis, the eggs containing hens immunized by the above method, usually the antibody-containing powder obtained from the yolk, have activity against the antigen. It is effective in protecting calf and piglets from the same bacterial attack used to immunize. Therefore, this powder is used to prevent or treat intestinal infectious diseases such as Escherichia coli and Skaur by oral administration.

Specific antibody-containing materials are also used in livestock and poultry feed additives, cosmetics, pharmaceuticals and serum diagnostics.

In another embodiment of the present invention, the emulsion of the yolk, white or whole egg of the immunized hen is separated by ultrafiltration into fractions of molecular weight 10,000 or less and the remaining fractions with larger diamagnetic weight. The fraction of electrons having a molecular weight of 10,000 or less is used to recover a material containing a transition factor component specific for the antigen, while the remaining fractions containing immunoglobulins having a molecular weight of about 150,000 or more are described in the above-described procedure. That is, it is used to prepare a specific antibody-containing material by the process of directly drying the fraction into a powder.

The separation by ultrafiltration is carried out, for example, in the following manner. Addition of 1N forest to the emulsion of yolks, whites or whole eggs containing specific antibodies, for example to pH 4.5, is sufficient for precipitation. After removing the precipitate by high speed centrifugation, the supernatant is neutralized with 1N NaOH. Acidification and neutralization are preferably carried out with gentle stirring. Instead of acidification and subsequent neutralization, it may be treated with an organic solvent such as chloroform. The supernatant is then passed through an ultrafilter having a pore size through which molecules of molecular weight of 10,000 or less can pass. This pore size is approximately 0.45 microns. As long as ultrafiltration is effective in removing all immunoglobulins, viruses, mycoplasmas and bacteria, the pore size of the ultrafilter can be varied. The fractions that passed through the ultrafilter are collected. The collected fractions, i.e., the filtrate, contain a transfactor component as an active ingredient specific for the antigen used for immunization. This filtrate does not contain any virus, mycoplasma, bacteria or immunoglobulin. All these processes are preferably carried out at a temperature not too high above room temperature (eg 0-25 ° C.). The filtrate thus obtained is used as a material containing the transition factor component according to the present invention and is stored as a solution or dried in powder or granule form by conventional methods such as lyophilization.

The materials containing the components of the transfer factor thus obtained are useful for the treatment and prevention of various infectious diseases and for feed additives, cosmetics and medicines for livestock and poultry. Since this material does not contain any antibodies or immunoglobulins, it can be administered parenterally without the need to obtain resistance to the antibody in advance and also without the risk of causing serum disease and sensitivity shock. Therefore, this material is useful for the treatment and prevention of various infectious diseases and other diseases in the intestine, and such administration can be administered whenever necessary.

To date, the immunological function of the transition factor components contained within the fractions of molecular weight 10,000 or less has not been achieved. In addition to the transition factor component, this fraction is thought to contain nutrients having a molecular weight of about 1200 or less described in US Pat. No. 4,402,938. It is possible that some of the transfactor components may be the same as the nutritional factors described in the above-mentioned US patent. Therefore, the fraction containing the specific transfer factor component is assumed to be useful as a nutritional supplement such as the nutritional factors of the United States.

As described above, the remaining fractions that do not pass ultrafiltration contain immunoglobulins, which are used to prepare antibody-containing powders by drying to powder in a conventional manner. If desired, the remaining fractions or yolks, whites or whole bodies containing specific antibodies can be subjected to conventional fractionation or tableting procedures before they are dried to powder. The specific antibody-containing material can be recovered as an emulsion or as a solution without drying into a powder, but for ease of storage it is convenient and desirable to recover as a solid such as a powder or granules.

According to the method of the present invention, since the animal used to immunize is a hen, many animals are readily available for immunization against the selected antigen, and many different antigens can be readily used simultaneously to produce antibodies. Therefore, a material containing a specific antibody or a specific transition factor material can be produced inexpensively in large quantities at any season of the year. It is also possible to deliberately prepare a number of materials containing different kinds of specific antibodies at the same time.

In a preferred embodiment of the method for producing an antibody-containing material, the yolk of an immunized hen. The white or whole body is simply dried after homogenization to form a powder, so that the desired product is obtained without a fractionation process such as ultrafiltration. This embodiment is particularly advantageous because of the very simple process. When an adjuvant is administered with an antigen in an immunized hen, it is possible for the antibody to be retained in the egg for a prolonged period of time with a high antibody titer against the antigen, thereby making it possible to produce the desired material very effectively and inexpensively.

When bacteria causing an intestinal infectious disease as an antigen are used to immunize a hen, oral administration of the antibody-containing material according to the present invention can treat and prevent intestinal infectious diseases such as Escherichia coli and diarrhea in livestock. Administration to the animal can be performed at any time without the animal having to acquire resistance to the oocyte antibody. When the antibody-containing material is recovered directly from the egg yolk, egg white or whole egg without undergoing the fractionation process, the material contains a transfactor component contained in a fraction having a molecular weight of 10,000 or less in addition to the specific antibody to the antigen. It contains. This material is therefore useful for nutritional supplements, or animal feed additives, cosmetics and pharmaceuticals.

In the following examples, the present invention will be further described. The invention is not limited to the details in the following examples.

Example 1

This example describes a method for preparing yolk powder containing specific antibodies from the eggs of immunized hens.

The 987P antigen, E. coli (E. coli), known to cause diarrhea in pigs, was injected intramuscularly into the experimental mature hens in an amount of about 1.5 mg per hen so that the hens were initially immune to the antigen. An adjuvant was used in combination with the antigen, in the form of an emulsion containing water in the oil and containing dead Mycobacterium tuberculosis cells. Four weeks after the first immunization, the same antigen and an adjuvant were injected in the same manner in an amount of about 1.5 mg per animal as a promoter. The yolk samples of the eggs laid by these hens were tested by antibody assay using aggregation reaction with antigens to confirm the presence of specific antibodies to antigens in the eggs. Antibody titer of each yolk sample was measured by the well-known method using an aggregation reaction. The rate of weekly change in the titration of the antibody in the yolk of the immunized hen after first immunization is shown in FIG. From the graph of FIG. 1, it can be seen that the titrant of the yolk antibody titers reaches the maximal value 8 weeks after the first immunization.

In addition, using the K88 and K99 of E. coli bacteria that cause swine diarrhea as another antigen, the experimental mature hens were immunized against the selected antigen by the same method described above, and the presence of specific antibodies against the antigen of egg yolk and The antibody titer was also measured in the same manner. Even in this experiment, the titer of antibody reached its maximum after some period of time.

After the titration of the antibody in the yolk reached the maximal value, the eggs of the immunized hens were collected to prepare the antibody-containing yolk as follows.

Eggs of hens immunized against the same antigen were collected and these egg yellows were isolated and combined together. The blended yolk was then homogenized and the yolk homogenate was immediately spray dried to a powder to recover as an antibody containing product. This powder was stored at 37 ° C. in the atmosphere.

The stability of the antibody-containing yolk powder stored at 37 ° C. was evaluated as follows. One gram of yolk powder sample before and after storage at different times was dispersed in 9 ml of PBS (phosphate-buffered salt) and the same amount of chloroform was added to this dispersion. The mixture was shaken thoroughly and then centrifuged at 3000 rpm for 20 minutes. The solution which floated on the surface was collected as an antibody containing fraction, and the antibody titer of the solution which floated on this surface was measured by aggregation reaction with an antigen. The results are shown in Table 1 below.

As can be seen from Table 1, antibody titers remained unchanged for at least 6 months of storage in all different powder productions derived from different antigens.

The antibody-containing yolk powder thus obtained can be orally administered to animals and is useful for the treatment and prevention of E. coli and diarrhea in animals (especially pigs). This yolk powder is also useful as an animal feed additive.

TABLE 1

Antibody titration before and after storage

Example 2

This example describes a method of making a material containing a transfactor component that is specific for an antigen used to immunize a hen.

The mature hens were immunized against 987P ⁺ ETEC in the manner described in Example 1 and eggs were collected after reaching the maximal value of the antibiotic titer in the egg yolk of the immunized hen. The whole (eg yolk and white) of eggs containing specific antibodies against 987P ⁺ ETEC was stirred by about 5 Kg to form an egg emulsion. The egg emulsion was diluted with the same amount of PBS and stirred with a mixer for 15 minutes. 1N hydrochloric acid was added to the diluted egg emulsion to adjust the pH to 4.5, and the emulsion was further stirred for 15 minutes. Precipitated solids were removed by high speed centrifugation. The supernatant was neutralized with 1N NaOH solution and then passed through an ultrafilter having a pore size of 0.45 microns to collect fractions having a molecular weight of less than about 10,000. The collected fractions contained a transfactor component that was specific for the antigen (987P ⁺ ETEC) used to immunize.

Example 3

This example illustrates the therapeutic function of the antibody-containing egg yolk powder obtained in Example 1 from hens immunized against 987P antigen of swine ETEC.

To each newborn pig weighing 0.97 to 1.8 Kg already fed colostrum, 1.5 g of the spray-dried yolk powder obtained in Example 1 containing a specific antibody to 987P ⁺ ETEC antigen and having an titer of 1000 antibodies was given to animals. Whenever artificial oil was fed three times a day, it was administered as a solution of this artificial oil. The yolk powder administration, which was performed three times a day by the above method, continued until the end of the experiment on the animals of the administration group. Newly born animals 21 to 23 hours old were challenged by the same 987P antigens used to immunize hens by oral administration of an antigen at an oral dose of 2 × 10 ¹⁰ cells per animal. Each newborn pig in the control group was attacked by the antigen in the same manner while eating the same artificial oil in which the antibody-containing yolk powder was not dissolved.

The rate of change of body temperature, clinical symptoms, weight gain, and isolation rate of challenge bacteria of each experimental animal were evaluated, and the results are shown in FIGS. 2 and 3 and Tables 2-4.

From FIG. 2, which shows the temperature change rate of the experimental animals after the challenge with antigen 987P ⁺ ETEC, it can be seen that the body temperature of the administration group animals was initially reduced but soon returned to the original level (about 2 days after the attack). On the other hand, the recovery of body temperature of control animals required a longer period of days.

The clinical symptoms of post-aggression fecal status are shown in Table 2, from which the excreta of all animals in the treatment group became normal only 3 days after the challenge, whereas the control excreta animals were excreted 5 days later. None have ever been normal and some animals died within five days of the attack.

The same trend can be seen in the results of Tables 3 and 4, which show the separation rate of the attack bacteria from the feces and small intestine. For all animals in the administration group, bacteria were not isolated from feces or small intestines. On the other hand, in all animals in the control group, bacteria grew in feces and small intestine.

Referring to FIG. 3, which shows the weight gain rates of newborn pigs in the administration group and the control group, the weight gain rate of the pigs in the administration group was temporarily reduced 22 hours after the attack, but returned to normal levels two days after birth. On the other hand, the weight gain rate of the control pigs decreased rapidly after the attack, and lasted up to 4 days after birth.

Therefore, it became clear from the above results that the specific antibody-containing yolk powder according to the present invention has a therapeutic function in protecting animals from attack by antigens used to immunize hens.

TABLE 2

Clinical Symptoms After Attack by 987P ⁺ ETEC

Symptoms: 0 = normal feces 1 = thin feces (no form)

2 = mild diarrhea (no form) 4 = death

3 = severe watery diarrhea

TABLE 3

Isolation Rate of Aggressive Bacteria from Excretion in Dose Control Group Pigs

The calculation is based on the percentage of offending bacterial colonies on DHL agar medium.

-= Attack Bacteria 50%:-= Attack Bacteria 80%:-= Attack Bacteria 100%

TABLE 4

Isolation of Aggressive Bacteria from Small Intestine Contents in Dosing and Controlling Pigs

Calculations are based on the percentage of offending bacterial colonies on DHL agar media.

-= Challenge Bacteria 50%:-= Challenge Bacteria 80%:-= Challenge Bacteria 100%

* When killed in animals 5 and 7, samples are taken 5 days after bacterial attack in other animals.

The action of the material containing the specific antibody or transition factor component according to the present invention is also effective for humans. Therefore, this material can be applied to animals, including humans.

As mentioned above, the preferred embodiment of the present invention has been described. However, many modifications may be made without departing from the spirit of the invention and such modifications are included within the scope of the invention.

Claims (15)

a) inoculating a hen with the selected antigen to immunize the antigen thereby generating a specific antibody to the antigen in the hen body; b) collecting eggs laid by the hen after the specific antibody is produced in the egg; And c) a specific antibody-containing material, i.e. a material containing a specific antibody active against an antigen used to immunize a hen, wherein all parts or fractions of the whole, yolk or white of the egg containing the specific antibody ( A method for producing a specific antibody-containing material from eggs, comprising the steps of recovering the fraction. The method of claim 1, wherein the hen is inoculated with the antigen together with a water-in-oil emulsion adjuvant. The method according to claim 1 or 2, wherein all parts of the egg whole, yolk or white of the egg are recovered as a specific antibody-containing material without undergoing fractionation. The method of claim 3, wherein the specific antibody-containing material is recovered in the form of a powder by stirring all parts of the egg whole, yolk or white of the egg to form an emulsion, and drying the emulsion to form a powder. . The method according to claim 1 or 2, wherein the fraction of whole, yolk or white of the egg containing the specific antibody is recovered as a specific antibody-containing agent. The method of claim 1, wherein the antigen is selected from the group consisting of pollen, bacteria, viruses, fungi, allegren, blood, sperm and toxins extracted from diseased animals. The method of claim 6, wherein the antigen is E. coli bacteria that cause an intestinal infectious disease in an animal. 8. The method of claim 7, wherein the antigen is selected from inactive antigens, supervisory antigens, and subunit antigens. a) inoculating a hen with the selected antigen to immunize the antigen thereby generating a specific antibody to the antigen in the hen body; b) collecting the eggs laid by the hen after the specific antibody is produced in the egg; c) recovering the whole, yolk or white of the egg containing the specific antibody; And d) isolating said fraction, a fraction containing a molecular weight of 10,000 or less in the whole egg, yolk, or egg white of the recovered egg, i.e. a material containing a transfer factor component specific for the antigen used to immunize the hen. A method for producing a specific transfer factor component-containing material, comprising the steps. The method according to claim 10, wherein the separation of the fraction is carried out by stirring the whole egg, yolk or egg white of the egg with or without diluent to form an emulsion, treating the emulsion with acid and then neutralizing the emulsion or Treatment to remove the solids precipitated by centrifugation, and ultrafiltration of the supernatant to separate fractions having a molecular weight of 10,000 or less, and recovering them as materials containing specific transition factor components. Manufacturing method. The method according to claim 9 or 10, wherein the hen is inoculated with the antigen together with an emulsion adjuvant containing water in the oil. The method of claim 9, wherein the antigen is selected from the group consisting of pollen, bacteria, viruses, fungi, allergens, blood, sperm and toxins extracted from diseased animals. The method of claim 12, wherein the antigen is selected from inert antigens, supervisory antigens and subunit antigens. An additive for animal feed consisting of a specific antibody-containing material prepared by the method of claim 1. An animal feed additive comprising a material containing a specific transfer factor component prepared by the method of claim 10.

Images